On May 10, 2025, Dr. Reddy's Laboratories Limited ("Dr. Reddy" or "the Company") announced its audited consolidated financial performance for the fourth quarter and full year of fiscal year 2024 (ending March 31, 2025). The report shows that the company achieved steady growth in its core businesses such as global generic medicines, pharmaceutical services, and active ingredients, and further consolidated its market position through strategic acquisitions.
In FY2025, the company’s total revenue reached INR 32,553.5 crore (USD 3.81 billion), a 16.6% increase compared to INR 27,916.4 crore in the previous fiscal year. Of this, the revenue for Q4 was INR 8,506 crore, a 20.1% year-over-year increase (Q4 FY2024: INR 7,083 crore). The global generics business (including biosimilars) accounted for INR 28,955 crore (89% of total revenue), growing 18%. Pharmaceutical services (including CDMO) and active pharmaceutical ingredients (API) contributed INR 4,323.5 crore, up 6.5%. Other businesses (including milestone revenues) declined to INR 213.7 crore due to strategic adjustments.
The full-year gross profit was INR 19,042.8 crore, with a gross margin of 58.5% (FY2024: INR 16,360.7 crore, gross margin 58.6%). Net profit after tax was INR 5,724.5 crore, up 2.8%, with net profit attributable to the parent company’s shareholders at INR 5,654.4 crore. Earnings per share (EPS) was INR 67.88 (FY2024: INR 66.93).
Operational Efficiency
R&D Investment: Increased to INR 2,738 crore (8.4% of revenue), focusing on pipeline innovation.
Asset Impairment: Due to changes in market conditions, the company impaired certain intangible assets by INR 1,693 crore, including Haloette? (INR 907 crore) and products in the European/Indian markets (INR 288 crore).
Operating cash flow was INR 4,642.8 crore (FY2024: INR 4,543.3 crore).
Cash Reserves: Cash and cash equivalents at the end of the period totaled INR 1,465.4 crore, with short-term borrowings increasing to INR 3,804.5 crore, mainly used for acquisition financing.
Goodwill and Intangible Assets: Due to acquisitions, these rose sharply to INR 10,861 crore (FY2024: INR 4,120 crore).
In recent years, with the cooling of the US generic market, major Indian generic pharmaceutical giants have faced growth bottlenecks. To break through this bottleneck, these companies began considering transformation around 2020.
In August 2019, former COO and President of Active Pharmaceutical Ingredients Erez Israeli was appointed the new CEO. Israeli, an Israeli national with a PhD and MBA, previously worked at Teva and has extensive industry experience. After taking office, he quickly introduced a new strategy focusing on establishing leadership positions in specific regions, excellent operations, and continuous patient-centric product innovation. Strategic measures included: 1) developing difficult-to-manufacture or intellectual property-protected products; 2) focusing on first-to-market opportunities for branded generics and differentiating products, and collaborating with third parties in regions with immature sales capabilities; 3) ensuring strong development capabilities for non-branded generics, targeting first-to-market, difficult-to-manufacture, and technically challenging products; 4) accelerating global approvals for biosimilars through process development and clinical research; 5) focusing on products with proprietary intellectual property and technical/price advantages for the active ingredients business; 6) focusing on differentiated formulations and unmet clinical needs for patented drugs; 7) ensuring safety, quality, efficiency, and leadership in operations.
In the North American business, to avoid revenue declines due to market contraction, Israeli significantly increased ANDA submissions after taking office. In 2022, DRL gained market exclusivity for two lenalidomide formulations, and with this product and multiple new ANDA approvals, North American revenue grew by 36% year-over-year. To maintain this growth, Israeli also spent USD 105 million in 2023 to acquire Mayne Pharma’s US generics business. As a result, North American revenue further increased by 28% in 2023. In addition to strengthening the US market, Israeli also expanded development efforts in Europe and emerging markets, with European revenues growing 3.1 times from 2019 to 2024 to INR 35.9 billion, and Indian market revenue growing 1.86 times to INR 53.7 billion.
From a performance standpoint, Israeli’s strategy has proven to be very effective. DRL’s total revenue grew 1.6 times over six years to USD 3.81 billion, and net profit grew 2.6 times to USD 670 million. To ensure sustainable business growth, Israeli also increased focus on specialty drugs, OTC, and biosimilars, rapidly building a product portfolio through acquisitions, licensing, and regional rights purchases. Notably, DRL’s joint venture with Nestlé and acquisition of Haleon’s nicotine replacement therapy business were key highlights in the company’s performance growth for 2024.
